Welcome to Industry Focus, the show that dives into a different sector of the stock market every single day.

Today is Wednesday, May the 29th, and we're talking health care.

I'm your host Shannon Jones and I am joined via Skype

by health care guru Todd Campbell. Todd how's it going? Oh it's going great and I am just

really really excited to talk about some just incredibly innovative disruptive

new medicines that could become available. I mean this is just I love this topics and I love

doing these shows exactly for this reason.

I am so on point with you Todd in preparing for this show for this week. I always love coming

on week after week but for me when we talk about

innovation when we talk about really pushing the needle and driving better health

outcomes I get super excited so I've been waiting days to talk about this and

for our listeners today's show is really all

about the field of gene therapy. First we're going to be diving into what is

right now the most expensive drug out on the market or soon to come out on the market was

approved last week and we're also going to be talking about bio morin's updates

on their potential game changer hemophilia. So we're going to be diving into all of that, but let's kick things off with Novartis.

There's been a lot of buzz here, Todd, and a lot of splashy somewhat controversial headlines around Novartis that's

ticker symbol and V S and their gene therapy drug Zol JensenMA try that 10 times, but this is a drug, one and done therapy that truly

has the potential to change lives.

Todd, we've been talking about this drug on the show before.

You pointed this out last Friday when the approval came through that this is not only a game

changer for Novartis, for another company we've been talking about, Regen Bio, but really truly a huge win for patients.

...